I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

While most master protocols for COVID-19 have converged on an overlapping set of experimental therapies, the COVID R&D Alliance’s adaptive trial is kicking off with five therapeutic targets largely untouched in the indication.

Three members of the alliance of more 20 companies -- AbbVie Inc. (NYSE:ABBV), Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) and Amgen Inc. (NASDAQ:AMGN) -- announced Monday the enrollment of the first patients in the Phase II I-SPY COVID study to treat severely ill, hospitalized COVID-19 patients who require high-flow oxygen...